Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

recurrent Soft Tissue Sarcoma

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of Recurrent Soft Tissue Sarcoma

Broader topic: Soft Tissue Sarcoma

Source population
Not part of this definition
Disease extent
recurrent
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      prior therapy
      status
      stated
    derivation status
    source-attested
    derivation note
    Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
    source wording
    Treatment of Recurrent Soft Tissue Sarcoma

    Study evidence for this setting

    24 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT00112463 · Registry condition search · Scope: unclear

    Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma

    4 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT00245102 · Registry condition search · Scope: unclear

    Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

    1 outcome links · 6 safety-group records · 0 quality-of-life measures

    →

    NCT00390234 · Registry condition search · Scope: unclear

    Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

    5 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT00659360 · Registry condition search · Scope: unclear

    AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT00831844 · Registry condition search · Scope: unclear

    Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

    1 outcome links · 10 safety-group records · 0 quality-of-life measures

    →

    NCT01079832 · Registry condition search · Scope: unclear

    Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies

    5 outcome links · 1 safety-group records · 1 quality-of-life measures

    →

    NCT01154452 · Registry condition search · Scope: unclear

    Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

    3 outcome links · 4 safety-group records · 0 quality-of-life measures

    →

    NCT01210222 · Registry condition search · Scope: unclear

    Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

    5 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT01532687 · Registry condition search · Scope: unclear

    Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

    4 outcome links · 3 safety-group records · 0 quality-of-life measures

    →

    NCT01553539 · Registry condition search · Scope: unclear

    Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery

    5 outcome links · 1 safety-group records · 1 quality-of-life measures

    →

    NCT01586104 · Registry condition search · Scope: unclear

    Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases

    3 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT01653028 · Registry condition search · Scope: unclear

    Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

    4 outcome links · 5 safety-group records · 0 quality-of-life measures

    →

    NCT02601209 · Registry condition search · Scope: unclear

    Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

    6 outcome links · 7 safety-group records · 0 quality-of-life measures

    →

    NCT02601950 · Source cited / selected · Scope: unclear

    A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

    6 outcome links · 8 safety-group records · 0 quality-of-life measures

    →

    NCT03154190 · Registry condition search · Scope: unclear

    Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

    6 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT03213665 · Source cited / selected · Scope: unclear

    Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A

    5 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT03213678 · Registry condition search · Scope: unclear

    Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATC

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT03213704 · Registry condition search · Scope: unclear

    Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment

    5 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT03245450 · Source cited / selected · Scope: unclear

    Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

    6 outcome links · 7 safety-group records · 0 quality-of-life measures

    →

    NCT03441360 · Source cited / selected · Scope: unclear

    Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sar

    6 outcome links · 3 safety-group records · 0 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice